Feryal Al-Saber,1 Waleed Aldosari,1 Mariam Alselaiti,1 Hesham Khalfan,1 Ahmed Kaladari,1 Ghulam Khan,2 George Harb,3 Riyadh Rehani,2 Sizuka Kudo,4 Aya Koda,4 Tohru Tanaka,4 Motowo Nakajima4 et al.
This study in patients with type 2 diabetes mellitus living in Bahrain supports that use of 5-ALA-SFC up to 200 mg per day taken as 2 divided doses is safe in patients taking concomitant oral antidiabetic medications. 5-ALA-SFC may offer benefits in the diabetic population, and larger studies enrolling a greater number of patients over longer periods of time are required to further define the effect of 5-ALA-SFC on glycemic control in this population.
This study was sponsored by SBI Pharmaceuticals Co., Ltd., and was conducted with the support of DZS Clinical Services as the Contract Research Organization overseeing study monitoring and management, data management and analysis, medical monitoring, and technical writing including support for manuscript preparation. The authors express special thanks to Ms. Maria Paluselli for her excellent medical writing assistance.
Journal Abstract: https://www.hindawi.com/journals/jdr/2016/8294805/